A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling

CompletedOBSERVATIONAL
Enrollment

74

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

July 22, 2021

Study Completion Date

August 20, 2021

Conditions
Movement DisordersParkinson DiseaseEssential TremorTremorDystonia
Interventions
DEVICE

Infinity DBS System with MR Conditional labelling

Patients implanted with the Infinity DBS system with MR Conditional labeling

Trial Locations (16)

22042

Inova Fairfax Hospital, Falls Church

22185

Universitetsjukhuset I Lund, Lund

28006

Hospital Universitario de la Princesa, Madrid

30322

Emory University Hospital, Atlanta

40225

Medizinische Einrichtungen der Universität Düsseldorf, Düsseldorf

45324

Wright State University & Premier Health, Fairborn

55131

Universitatsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

63003

CHU Gabriel Montpied, Clermont-Ferrand

71103

Willis-Knighton Medical Center, Shreveport

72076

Universitäts Klinikum Tübingen, Tübingen

75185

Akademiska sjukhuset, Uppsala

80045

University of Colorado Hospital, Aurora

80122

Neurosurgery One, Littleton

85724

Banner University Medical Center Tucson Campus, Tucson

99202

Inland Northwest Research, Spokane

08901

Robert Wood Johnson University Hospital, New Brunswick

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY

NCT03884231 - A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling | Biotech Hunter | Biotech Hunter